Cyclerion Therapeutics Inc.
13F holders, Q1 2024 (March 31)15holders
$3.20avg. 13F price*
At the end of Q1 2024, 15 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings. The largest holders were Slate Path Capital LP ($1.1M), MFN Partners Management, LP ($542K) and Tyndall Capital Partners L P ($527K).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $106 |
| Exits | 1 | $626 |
Ownership 15 holders
| Slate Path Capital LP | 0.02% | No change | 357,880 | $1.1M |
| MFN Partners Management, LP | 0.02% | No change | 169,460 | $542K |
| Tyndall Capital Partners L P | 100.00% | Add +0.2% | 164,777 | $527K |
| FMR LLC | 0.00% | Reduce -0.3% | 162,327 | $519K |
| Artal Group S.A. | 0.01% | No change | 138,955 | $445K |
| Geode Capital Management, LLC | 0.00% | Add +2.6% | 32,082 | $103K |
| Vanguard Group Inc. | 0.00% | No change | 23,490 | $75K |
| BlackRock Inc. | 0.00% | No change | 17,169 | $55K |
| UBS Group AG | 0.00% | Add +13.3% | 2,524 | $8K |
| Morgan Stanley | 0.00% | Reduce -7.0% | 649 | $2K |
| Group One Trading LLC | 0.00% | No change | 540 | $2K |
| Royal Bank of Canada | 0.00% | Add +6.7% | 352 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 33 | $106 |
| Wells Fargo & Company | 0.00% | No change | 15 | $48 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.